This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

THEODORE W. AVRUSKIN, MD; VINOD LALA, MD; SHIU-C. TANG, MD; CHRISTINA S. JUAN

Am J Dis Child. 1979;133(5):553-555.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Methylphenidate (Ritalin) hydrochloride, a CNS stimulant, is being used with increasing frequency in children with the hyperkinetic syndrome. More than 150,000 children were treated in 1973 and this number is increasing rapidly.¹ Recent reports have noted a slowing of growth in hyperactive children given stimulant drugs. Safer et al^2-4 noted a retardation in both weight and height increase in 63 hyperactive children who were given either dextroamphetamine or methylphenidate for two years. Additionally, they noted that 13 of these children had a rebound weight gain with discontinuation of dextroamphetamíne therapy, a "less striking" growth suppression only when dosages of greater than 20 mg daily of methylphenidate were used. They also noted that increasing the dosage of stimulant used over time generally increased the degree of growth suppression.^3-4 Weiss et al⁵ reported no deleterious effect of methylphenidate on growth. Schain and Reynard⁶ reported that 40% of the . . . [Full Text PDF of this Article]

Author Affiliations
Division of Pediatric Endocrinology and Metabolism The Brookdale Hospital Medical Center Linden Blvd at Brookdale Plaza Brooklyn, NY 11212

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?